Oppenheimer: These 2 stocks could double, if not more
This is the last countdown. After the election of the President of the United States only two weeks later, the stress of the election year makes tours of Wall Street, but one professional claims that regardless of the result, an opportunity may arise. Oppenheimer̵
7;s chief investment strategist John Stolzfuss notes that in the final stage of the race for the White House, “markets seem to signal that no matter how strong the rhetoric on both sides and which side wins, investment opportunity in some form is likely to prevail over risk added after the opening day in January 2021. “He added:” In our experience, the opportunity often arises from uncertainty, while the perception of “security” often generates complacency. “As for the third quarter profit season, this is already surprising. up. Although it is still too early to say how the season will play out, Stoltzfus says “so far so good”. Data from last weekend showed that 84% of companies that have already reported exceeded profit expectations, and 82% exceeded revenue expectations for the quarter. Given Stoltzfus’ prospects, Oppenheimer analysts split the table into two stocks under the radar, noting that each could double or more next year. Using the TipRanks database, we found that the rest of the street is also on board, as everyone can boast a consensus rating of “Strong Purchase”. NeuBase Therapeutics (NBSE) Develops the next generation of gene suppression therapies with its flexible, highly specific synthetic antisense oligonucleotides, NeuBase Therapeutics wants to improve the lives of patients everywhere. Based on the strength of his platform, Oppenheimer believes that great things can be preserved. Company analyst Hartaj Singh highlights the Petidi-nucleic acid (PNA) AnTisense OLigonucleotide (PATrOL) platform, which allows rapid drug design for the treatment of various medical abnormalities, systemic delivery (IV), penetration of the blood-brain barrier, increased cell permeability. , access to genomic loci and secondary RNA structures, and the development of highly selective therapies, such as overcoming the technical limitations of first-generation antisense oligonucleotides (ASOs). We believe that in the deep potential of ASO for disease treatment, the current field of first-generation therapies creates an “obstacle” for a company like NBSE, where its technical advantages for ASO through the PATrOL platform can lead to better risk therapies. / benefit profile “, explained Singh. In addition, the long-tail redistribution of NBSE PNAs can have significant implications for dosing regimens for t hese agents (potentially weeks to months). Singh mentioned,” In combination with the improved drug ability to target through PNA, we continue to look at the potential of the PATrOL platform with the usual focus on the safety of such new drugs. ”After the first half of 2020,“ helped further validate ”this platform, the company stays with the leading candidate for Huntington’s Disease (HD), NT0100 Additional preclinical results and selection of candidates should come to YE 20. Considering the available preclinical NHP data, it maintains a broad biodistribution and rapid tissue uptake after systemic (IV) administration, an important feature of the platform, according to Singh. “As the delivery of therapeutic agents and their penetration into deep brain structures remain paramount for diseases such as HD, we are encouraged to arrive at additional PD data from preclinical models (Q4 2020) … Despite the early nature of these preclinical NHP PK “data and in vitro data for PD, we believe they strongly validate the approach that NeuBase has taken to develop a truly ‘better mousetrap’ and differentiate its technology from conventional ASOs,” he said. to bring forward and thus Singh has high hopes for NT0200, its product for HD and myotonic dystrophy (DM1). The DM1 lags behind the HD program by approximately six months. After the selection of candidates in 1H21, studies enabling IND can begin. Everything the NBSE is doing about it has made Singh leave his rating of superiority (ie buy) as it is. Along with the call, he maintains a price tag of $ 17, suggesting a 104% potential increase. (To view Singh’s recording, click here) Do other analysts agree? They are. In the last three months, only purchase ratings have been issued, namely 4. Therefore, the message is clear: the NBSE is a strong purchase. Given the target of an average price of $ 16.50, stocks could jump 97% next year. (See NBSE stock analysis for TipRanks) Prevail Therapeutics (PRVL) Then we have Prevail Therapeutics, which develops disease-modifying gene therapies for patients with Parkinson’s disease and other neurodegenerative disorders. After an impressive update on the pipeline’s progress, Oppenheimer likes what he sees. Introducing the company, analyst Jay Olson highlighted the encouraging data from the PROPEL phase 1 / 2a study, which evaluated its leading candidate PR001 in patients with Parkinson’s disease (PD) with a GBA1 mutation (PD-GBA). This mutation affects approximately 9% of all BP patients in the United States. More closely in the study, it included two patients with preliminary data showing normalization of CSF GCase activity in a month or three from undetectable baseline levels. According to Olson, this clearly implies clinical improvement. It should be noted that there were serious adverse events (SAEs) at month-three, possibly related to the AAV9 capsid immune response, that were resolved. However, the analyst claims that the immune response in AAV9 gene therapies is normal and transient. In addition, PRVL submitted an amendment to the PROPEL study protocol and recording is expected to continue in 2H20. The company wants to change the design of an open-label study targeting 12 patients, including the two current patients, and plans to optimize the immunosuppressive regimen to save on steroid use. To that end, bi-monthly safety data and biomarkers for a subset of patients will be available by mid-2021. If therapy is eventually approved for this indication, Olson sees a possible 2,035 unadjusted sales of $ 8 billion. On top of that, activity normalization of CSF GCase in the fourth month of undetectable baseline levels was also observed in Gaucher disease (GD2) patient of PR001 as part of a compassionate use program. This rare inherited lysosomal disorder is also caused by autosomal recessive inheritance in the GBA1 gene. According to Olson, this result gives a positive reading of the Phase 1/2 PROVIDE study in GD2 initiated in 2H20. “Because GD2 is an ultra-rare disease that affects infants and leads to a very short life expectancy, we believe that the indication GD2 has a shorter regulatory pathway than other indications associated with GBA1. We believe that the approval of PR001, if clinically successful, could happen in 2024, due to the lack of treatment for patients with GD2, “he said. Moreover, the Phase 1/2 PROCLAIM study of PR006, its therapy for GRN frontotemporal dementia (GRN-FTD), is expected to begin in 2H20, with bi-monthly reporting of biomarkers from a subset of patients scheduled for late 2020 or early 2021 Given all of the above, Olson said, “We look at the stock price at an attractive entry point, while PRVL remains well-capitalized with $ 131 million in cash, providing a runway for 1H22.” is a surprise that Olson stays with the bulls. In addition to a rating for superiority (ie buying), he left a price price of $ 25 per share. Investors can gain a profit of 156% if this goal is met in the next twelve months. (To watch Olson’s story, click here) In general, other analysts echo Olson’s mood. 5 purchases and no retentions or sales are added to the strong purchase rating. At an average price of $ 23.25, the potential for growth is 139%. (See PRVL stock analysis for TipRanks.) To find good stock trading ideas for attractive ratings, visit TipRanks’ Best Buy Shares, a newly created tool that brings together all insights into TipRanks ownership. Disclaimer: The views expressed in this article are those of the analysts submitted. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.